NYBC Ventures
Corporate VCNew York · Seed–Series B · 8 people tracked
Find your way into NYBC Ventures
547 people in our graph share verified history with the NYBC Ventures team — schools, employers, funds. One of them is your warm intro.
Investment thesis
NYBC Ventures is a corporate venture fund launched by New York Blood Center Enterprises with a $50M commitment to accelerate breakthroughs in blood and cellular therapies and supporting technologies. It leverages New York Blood Center's decades of expertise in blood products, transfusion services, and cell and gene therapy manufacturing. The fund targets early to mid stage innovations across hematology, transfusion medicine, cell therapy, and infectious disease, supporting therapeutics, devices, and other breakthrough solutions that address key challenges in these fields and ultimately improve patient lives.
Source: firm website, verified Aug 7, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 14 of 15 portfolio companiesBiotech ×12Healthtech ×10Medical Devices ×8Deep Tech ×6Longevity ×3Advanced Manufacturing ×2Digital Health ×2Robotics ×2
HQs:United States×9United Kingdom×1Netherlands×1
Investments · 15 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12019 · 12018 · 14 dated
STRM.BIO develops technology to deliver gene therapies, aiming to improve how these treatments reach patients.
BiotechDeep TechHealthtechLongevityMedical Devices
Michael Luther(CEO)in
Co-investorsAscension VenturesBreakout LabsBreakout VenturesDelos CapitalKdT Ventures
Akadeum manufactures GMP-compliant ancillary materials for cell and gene therapy applications, specializing in microbubble-based negative selection products.
Advanced ManufacturingBiotechDeep TechHealthtechMedical DevicesAnn Arbor, US
Kalyan Handique(Executive Officer, Director)John Younger(Executive Officer, Director)inJames Militello(Executive Officer)
BoardJeffrey S. Williams(Director)Paul D'Amato(Director)Dan Kidle(Director)in
Co-investorsArboretum VenturesBeringeaBerkeley CatalystBlueStone Venture PartnerseLab VenturesID Ventures+5 more
Aronora is a clinical-stage biotech developing antithrombotic therapies, including factor XI/XIa inhibitors and thrombolytic drug candidates, to treat and manage thrombotic and thromboembolic conditions such as acute ischemic stroke, heart attack, and pulmonary embolism.
BiotechDeep TechHealthtechPortland, US
Erik I. Tucker(President & Chief Executive Officer)in
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform.
BiotechLongevityMedical Devices
Andrew Schiermeier(Chief Executive Officer)in
Co-investorsNovo HoldingsBlackstone Life SciencesEight Roads VenturesF-Prime Capital
Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.
Advanced ManufacturingBiotechRoboticsCambridge, GB
Co-investorsHighland EuropeTTP Ventures
A blood bank and laboratory services provider supplying blood products including red blood cells, plasma, and platelets to hospitals and medical facilities, alongside laboratory testing services and specialty clinical procedures.
BiotechHealthtechMedical DevicesNew York, US
Functional Fluidics is a CLIA-certified diagnostic lab offering proprietary red blood cell function biomarker assays, starting with Sickle Cell Disease.
BiotechDigital HealthHealthtechMedical DevicesDetroit, US
Patrick Hines(CEO & Founder)inDr. Hines(Founder)John Cunningham(Chief Operating Officer)in
Co-investorsID VenturesMichigan RiseSeae VenturesWavemaker Three-Sixty Health
A healthcare-focused investment firm managing approximately $2 billion in assets across 52 portfolio companies.
Digital HealthHealthtechMedical Devices
Co-investorsUnion Grove Venture Partners
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)Sean Ainsworth(Chief Executive Officer)Robert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)inScott McIvor(Chief Development Officer)Eric Garcia(Executive Officer)
Co-investorsBioRock VenturesBoston Harbor AngelsBreakout VenturesEQx FundInvariantes FundMichigan Capital Network+1 more
KaloCyte develops ErythroMer, a dried, shelf-stable artificial red blood cell for use in emergency and trauma care when stored blood is unavailable or in short supply.
BiotechDeep TechHealthtechMedical DevicesBaltimore, US
Allan Doctor(Co-Founder & CSO)inDipanjan Pan(Co-Founder, Chief Technical Officer)inPhilip Spinella(Co-Founder, Chief Medical Officer)inDaniel Getman(Director)Gregory Lanza(Director)
Co-investorsBioAdvanceBioGenerator VenturesMaryland TEDCOOld Line Capital PartnersTEDCO
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)Michelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesAgent Capital+8 more
Thymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease.
AI & Machine LearningBiotechLongevityCambridge, US
Stan Wang(MD, PhD)inBing Lim(MD, PhD)inManish Jainin
Co-investorsPillar VC
Vitestro is a Netherlands-based medical robotics company that develops Aletta, an autonomous robotic phlebotomy device for diagnostic blood collection in hospitals and laboratories.
HealthtechMedical DevicesRoboticsNetherlands, NL
Toon Overbeeke(Co-founder & CEO)inBrian Joseph(Co-founder)in
Co-investorsSonder Capital
Portfolio news
latest coverage across their companiesImmusoft · immusoft.com · Mar 30, 2026
Star Therapeutics · pharmaceutical-technology.com · Oct 1, 2025
Frequently asked questions
- How many investments has NYBC Ventures made?
- NYBC Ventures has 13 tracked investments, including 1 dated in the last 24 months.
- What stage does NYBC Ventures invest at?
- NYBC Ventures invests at the Seed, Series A, Series B stages.
- What sectors does NYBC Ventures focus on?
- NYBC Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is NYBC Ventures located?
- NYBC Ventures is headquartered in New York, US.
- Does NYBC Ventures lead rounds?
- NYBC Ventures typically participates in rounds rather than leading them.
- Who does NYBC Ventures co-invest with?
- NYBC Ventures most often shares deals with Breakout Ventures, ID Ventures, Michigan Capital Network, among 33 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.